KEYTRUDA (Pembrolizumab) Plus Chemotherapy Before Surgery and Continued as Single Agent After Surgery Reduced Risk of Death by More Than One-Third (34%) Versus Neoadjuvant Chemotherapy in High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC)

BusinesswireSep 15 10:30 ET

Express News | Keytruda® (Pembrolizumab) Plus Chemotherapy Before Surgery and Continued as Single Agent After Surgery Reduced Risk of Death by More Than One-Third (34%) Versus Neoadjuvant Chemotherapy in High-Risk Early-Stage Triple-Negative Breast Cancer (Tnbc)

ReutersSep 15 10:30 ET

Do Queasy Side Effects Mean the End of Weight-loss Drug Stock Hype?

Seeking AlphaSep 15 10:07 ET

Express News | Merck & Co Inc - Keytruda Reduces Risk of Death by 29% in Advanced Melanoma

ReutersSep 15 08:50 ET

Express News | Ten-Year Data for Merck’s Keytruda® (Pembrolizumab) Demonstrates Sustained Overall Survival Benefit Versus Ipilimumab in Advanced Melanoma

ReutersSep 15 08:45 ET

Ten-Year Data for Merck's KEYTRUDA (Pembrolizumab) Demonstrates Sustained Overall Survival Benefit Versus Ipilimumab in Advanced Melanoma

BusinesswireSep 15 08:45 ET